Federal Cannabis Legislation and Regulation. Attend this session for an overview of developments in federal cannabis legislation and regulation. Panelists will address new bills, reintroductions, and what is likely to move.
Attendees will leave this panel with a deeper understanding of the current hemp and CBD legislation and proposed legislative solutions to current regulatory and legal challenges facing the hemp and hemp-derived cannabinoid industries. Panelists will do a deep dive into current legislative proposals, as well as approaches for the 2023 Farm Bill.
Navigating the Highs and Lows of Cannabis Regulatory Compliance—Insights, Best Practices, and Hurdles. Examine regulatory compliance “hot topics”, including maintaining state licenses and navigating enforcement actions, and explore best practices for corporate governance, novel partnership agreements such as IP licensing and white labeling, and regulatory considerations of various exit strategies for mature cannabis enterprises.
Learn about the licensing considerations, continuing obligations, and risk related to physical security in the cannabis industry, from mapping your business to liaising with law enforcement, and from environmental and procedural security to best practices in security employee training, join us to go through the intricacies of security in the cannabis industry.
Focusing on the Cannabis Administration and Opportunity Act (CAOA), the Marijuana Opportunity Reinvestment and Expungement Act (MORE), and the States Reform Act (SRA), our panelists will discuss how these proposals would change how the the relevant agencies (such as USDA, FDA, TTB, and PTO) regulate the cannabis sector.
With legalization initiatives moving quickly in the Tri-State Area, prospective operators are gearing up for what will inevitably be a competitive licensing process. In this session, attorneys will delve into the laws in: New Jersey, New York, and Connecticut.
Our distinguished panel of judges will hear argument from both sides—petitioners and the government—and make a decision regarding the legality of marijuana’s continued classification as a Schedule I substance. Come see the exciting hearing unfold!
Two DC insiders, Saphira Galoob, Managing Director of the Liaison Group, and Amber Littlejohn, Executive Director of the Minority Cannabis Business Association, will discuss a bird's-eye view of Democratic and Republican approaches to federal cannabis reform.